This is an aggregated industry headline. Read the full story at FierceBiotech →
Jasper finds new purpose in merger with Kira, while offloading Tavneos rival to Mirador
Jasper Therapeutics is being reborn via a merger with Nasdaq-listed immune-mediated disease biotech Kira Pharmaceuticals.
By FierceBiotech
· Jul 19, 2026
· via FierceBiotech
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansion…
The WeekBriefing
Veradermics' oral minoxidil exceeded expectations in Phase 2, sending shares near $130 and strengthening its c…
The WeekSTAT News ↗
"I fear that the widespread rollout of testosterone screening may lead to some surprising and unintended conse…